Bidding war erupts over Dimension’s gene therapy pipeline as Ultragenyx counters Regenxbio deal – Endpoints News
Endpoints News |
Bidding war erupts over Dimension's gene therapy pipeline as Ultragenyx counters Regenxbio deal
Endpoints News A bidding war has suddenly erupted over one of the most damaged biotechs in gene therapy R&D. Just weeks after Regenxbio lined up the acquisition of Dimension Therapeutics $DMTX for , $86 million in stock, Ultragenyx $RARE has come along with an … |
